Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    Home»Business»Lawrence Ho’s Family Office Black Spade Capital Makes its First Move in the Medical IT Space via My Platform
    Business

    Lawrence Ho’s Family Office Black Spade Capital Makes its First Move in the Medical IT Space via My Platform

    Marie JonesBy Marie JonesJune 10, 2020Updated:June 10, 2020No Comments4 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Black Spade Capital Limited (“Black Spade Capital”), a family office managing the private investments of Mr. Lawrence Ho, Chairman and Chief Executive of Melco International Development Limited, has announced it has invested and held shares in My Platform, a medical IT services platform.

    Mr. Jesse Ho, CEO of My Platform

    Founded in Hong Kong as a start-up, My Platform was launched as a brand-new medical management system by marrying IT with the concept of smart medical care. The result is a one-stop resources sharing platform with real-time access that connects the many stakeholders in the traditional healthcare ecosystem. The enormous growth potential of My Platform has attracted various investors, among them Black Spade Capital, whose investment affirms the value of My Platform.

    Since its establishment in 2016, My Platform has been focusing on developing a simple and easy-to-use interface. With user experience in mind, the system allows users to master the clinic operating system in a short period of time. Be it a doctor, a medical group, an insurance company, a patient or the human resources department in an organization, users of My Platform can make use of the one-stop data management service to run analysis of different workflow from outpatient consultation to insurance claim. By constantly adding and customising system functionalities, not only does My Platform enhance user safety and operational efficiency, but it also saves time for performing diagnosis by doctors and healthcare practitioners. In response to the inconvenience and negative impact brought by the epidemic, My Platform has since been strengthening its service offerings and developing remote consultation services (“Telemedicine Services”).

    My Platform is one of the participating service providers under the D-Biz Programme launched by the Hong Kong SAR Government. It is committed to promoting a paperless medical work environment by transferring medical records and insurance information to cloud platform, thus allowing clinics to share resources. My Platform places great emphasis on data security so that users need not worry about any loss caused by computer malfunctioning. To shorten the lengthy process for medical insurance claims, My Platform enables doctors to directly connect with insurance companies such that both parties can choose their partners freely. By allowing real-time review and follow-up on claim status, the entire process becomes more transparent and the time lag from lodging a claim application to getting insurance compensation reduces significantly.

    My Platform boasts a mature operation system which is recognized and appreciated by many doctors. In 2018, the well-known medical group Virtus Medical (managed by Dr Manson Fok, son of the late Mr. Henry Fok Ying-Tung, a vice chairman of the Chinese People’s Political Consultative Conference (CPPCC)) took the lead to adopt the operation system of My Platform. At present, the system developed by My Platform is serving hundreds of general clinics, specialist clinics and radiology & imaging diagnostic centres in Hong Kong. It has also been adopted by reputable practitioners at Central Building, Hing Wai Building, Entertainment Building and the 15-storey Virtus Medical Tower (where the operation system of My Platform is adopted by practitioners in the entire building) in the Central district, as well as H Zentre (newly opened last year) and Hong Kong Pacific Center in Tsim Sha Tsui. In addition, the system of My Platform is also adopted by iRAD, one of the largest radiology & imaging diagnostic groups in Hong Kong, which further boosts the brand recognition of My Platform in the sector.

    To date, the operation of My Platform has expanded to first-tier cities in the Mainland China such as Beijing and Shenzhen. With the support of the business development centre in Guangzhou, My Platform is capable of seizing business opportunities in mainland cities and providing a quality management system to local high-end clinics. Looking to the future, My Platform will strive to roll out its service to different cities in China to make its service portfolio more accessible to all stakeholders.

    About Black Spade Capital Limited
    Black Spade Capital Limited is an established family office managing the private investments of Mr. Lawrence Ho. Headquartered in Hong Kong, its global portfolio consists of a wide spectrum of cross-border investments as it consistently seeks to add new projects and opportunities to its investment mix. Black Spade’s investment strategy maximizes coverage of geographic regions and sectors whilst maintaining a portfolio of diversified asset classes, ranging from equity, fixed income, medical technology, leisure and culture, green energy, real estate to Pre-IPO investments.

    Black Spade Capital Limited
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleAvance Clinical在2020年生物科技創新組織數字會議上表示,TrialTrove數據顯示,澳大利亞開始復工
    Next Article AppsFlyer Launches Zero, its Free-for-Life Software & APIs to Help Brands Tap into Their Owned Media

    Related Posts

    Savills Hong Kong Celebrates 40th Anniversary

    October 5, 2026

    Future-ready or Falling Behind? ICDM Study Identifies Five Imperatives for ASEAN Boards

    October 1, 2026

    New Zealand’s Missing Piece in the Smoke-Free Strategy

    September 29, 2026
    Add A Comment

    Comments are closed.

    Latest News

    • Micot’s XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal Disease
    • Savills Hong Kong Celebrates 40th Anniversary
    • Central New Energy (01735.HK) Receives MSCI Provisional ESG Rating of BB Under Semiconductor & Semiconductor Equipment Industry Model
    • American Wave Machines Files Patent Infringement Lawsuit Against WhiteWater West Industries
    • Datavault AI CEO to Present “Operating System for Tokenized Assets” at XRP Seoul 2026
    • Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localization Application by the Center for Drug Evaluation of China’s NMPA, Driving Continued Commercial Momentum
    • GA-ASI Demonstrates Disaster Relief Comms System With SoftBank Corp.
    • Future-ready or Falling Behind? ICDM Study Identifies Five Imperatives for ASEAN Boards
    • Graphene Manufacturing Group Provides Quarterly ATM Sales Update
    • JCB Enhances Cardmember Benefits in Malaysia Through Collaboration with IHH Healthcare Malaysia
    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.